Matinas BioPharma (MTNB) Q4 2024 Earnings
MTNB·Reported March 26, 2025·Before market open
Matinas BioPharma reported Q4 2024 revenue of $962.0K. Diluted EPS came in at $-1.50, missed the $-0.78 consensus by $0.72.
Revenue
$962.0K
Diluted EPS
$-1.50missed by $0.72
Consensus: $-0.78
SEC Filings
Earnings release8-K not filed yet
Quarterly report10-Q / 10-K not filed yet
Filings will appear here once submitted to SEC EDGAR.
Q4 2024 Earnings FAQ
Common questions about Matinas BioPharma's Q4 2024 earnings report.
Matinas BioPharma (MTNB) reported Q4 2024 earnings on March 26, 2025 before market open.
Matinas BioPharma reported revenue of $962.0K and diluted EPS of $-1.50 for Q4 2024.
EPS missed the consensus estimate of $-0.78 by $0.72.